RemeGen (HKG:9995, SHA:688331) posted net profit attributable to shareholders of the listed company of 610.9 million yuan for the third quarter of 2026, compared with a loss a year earlier.
Diluted earnings per share was 1.08 yuan, according to a Thursday Hong Kong bourse filing.
For the three months ended Sept. 30, operating revenue at the biopharmaceutical company was 910.5 million yuan, up 46% year over year.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments